real peptides FAQ

Do not use it. Cloudiness after reconstitution indicates one of three problems: the peptide aggregated due to improper storage or handling, the synthesis produced truncated or misfolded sequences that don't dissolve properly, or the vial contains contaminants (endotoxins, bacterial material, or synthesis byproducts). None of these scenarios produce reliable experimental results. Discard the vial, document the batch number, and contact the supplier for a replacement with verified purity testing. Cloudy reconstituted peptide is not salvageable by filtering or re-dissolving. The underlying problem is structural.

Check the vial immediately. If it's still cool to the touch and the fridge interior hasn't exceeded 10°C, the peptide is likely intact for continued use. If the fridge warmed above 15°C or you're unsure how long power was out, inspect the solution for cloudiness or precipitation. Those are signs of protein aggregation. Even if the solution looks clear, treat the vial as compromised: either use it within 5–7 days or discard it and reconstitute a fresh vial. Power outages create the exact thermal stress profile that denatures peptides without visible warning.

Discard the vial and contact the supplier immediately. Authentic lyophilised ipamorelin is white to off-white. Any yellow, grey, or brown discolouration indicates oxidative degradation, contamination with impurities, or exposure to elevated temperatures during storage or shipping. Degraded peptides lose biological activity and can produce toxic byproducts during metabolism. Even slight discolouration is a rejection criterion in pharmaceutical peptide QC. The same standard applies to research-grade compounds.

If the vial was at room temperature (20–25°C) for 8–12 hours, you've likely lost 10–15% potency but the peptide is still usable. Refrigerate it immediately and plan to use the vial within 7–10 days rather than the full 28-day window. If the room was warmer than 25°C or the vial sat out longer than 12 hours, assume more significant degradation. Consider discarding it if your research protocol requires precise dosing. Temperature-induced hydrolysis accelerates non-linearly: the first hour at 25°C causes minimal damage, but by hour 8 the peptide backbone is breaking down at detectable rates. Our team's guidance: one accidental overnight lapse doesn't destroy the vial, but don't let it happen twice.

Discard it immediately. Cloudiness in reconstituted peptide solutions indicates protein aggregation, microbial contamination, or particulate formation. All of which render the compound ineffective or unsafe. GHRP-2 solutions should be completely clear and colourless when properly reconstituted and stored. Attempting to use degraded peptide wastes research time and introduces uncontrolled variables. Clouding can result from temperature excursions during storage, improper reconstitution technique (injecting bacteriostatic water too forcefully), or expired lyophilised powder.

Discard it and source a new vial. Oxytocin loses approximately 10% potency per week at room temperature, meaning a 24-hour ambient exposure degrades the peptide by roughly 3–5%. This may seem minor, but trust protocol effects are dose-sensitive. A 5% potency loss in a 24 IU dose reduces effective dosing to approximately 23 IU, potentially dropping below the receptor saturation threshold required for consistent behavioural modulation. More critically, partial degradation creates a mixed solution of active peptide and inactive degradation products, introducing uncontrolled variables into your experimental design.

You're likely still on the initial titration dose (3mg or 6mg), which is sub-therapeutic. The starting doses exist to allow GI tolerance to develop, not to produce weight loss. Appetite suppression becomes noticeable for most patients by week 8–12 once the dose reaches 24mg or higher. If you reach 24mg and still feel no change in hunger signals, consider whether baseline dietary structure is masking the effect. Orforglipron delays gastric emptying, but eating highly processed foods every two hours overrides that mechanism entirely.

Transient hypotension (systolic drop of 10–15 mmHg) is expected and benign. Symptomatic hypotension (dizziness, fainting, confusion) indicates excessive vasodilation relative to your baseline cardiovascular reserve. Sit or lie down, hydrate with 16–24 ounces of water, and avoid standing quickly. If you have a history of orthostatic hypotension or are taking antihypertensive medications, reduce VIP dose by 30–40% and inject while already seated.

Rotate injection sites daily and confirm you're using bacteriostatic water, not sterile saline. Injection site reactions in 5–10% of users typically resolve within 72 hours and indicate an immune response to the peptide carrier solution rather than the active compound itself. If redness persists beyond four days or spreads beyond a 2cm radius, discontinue use and consult a medical professional. This may indicate contamination or an allergic response to copper in the GHK-Cu formulation.

Do not use it. Temperature excursions above 8°C for more than 4 hours cause measurable potency loss. Overnight at room temperature (8–12 hours at 20–25°C) likely degraded 30–50% of the peptide's bioactivity. The solution may still appear clear, but neutrophil recruitment and VEGF upregulation will be significantly reduced. Reconstitute a fresh vial and return it to refrigeration immediately after drawing your dose.

If fewer than 6 hours have passed since the scheduled dose, administer it immediately and continue the regular schedule. If more than 6 hours have passed, skip the missed dose and resume at the next scheduled time—do not double-dose to compensate. Doubling creates a plasma spike that exceeds the therapeutic window without extending duration, and it disrupts the twice-daily rhythm required to maintain consistent HGF pathway activation. Missing a single dose creates one 16–20 hour trough period, which temporarily reduces receptor occupancy but doesn't negate prior neuroplasticity gains.

Hair follicle regeneration operates on a 3–6 month timeline. Follicles entering anagen during weeks 6–8 of the protocol won't produce visible terminal hairs until 8–12 weeks post-injection. Assess outcomes at 12–16 weeks from protocol start, not at the end of the injection phase. If density remains unchanged at that point, the most common causes are: inadequate local tissue concentration (systemic injection instead of scalp-proximal), improper storage leading to peptide degradation, or baseline follicle miniaturization too advanced for VEGF-dependent rescue. TB-4 stimulates existing follicles in telogen-to-anagen transition. It does not regenerate follicles that have fully atrophied and lost dermal papilla structure.

Discard the vial immediately and do not use the solution. Cloudiness after reconstitution indicates protein aggregation, contamination with particulates, or the presence of excipients that destabilize the peptide structure in solution. Even slight turbidity suggests the peptide has denatured or contains impurities that will confound experimental results. Legitimate IGF-1 LR3 produces a solution as clear as sterile water. Any deviation from crystal clarity is a failure of quality standards. Request a replacement vial from the supplier and verify the new batch includes updated COA documentation showing HPLC and endotoxin testing.

Request the batch-specific CoA immediately and verify all six documentation elements listed earlier. If the supplier cannot provide HPLC chromatograms, mass spectrometry data, and endotoxin testing within 48 hours, assume the product is unverified at minimum and potentially counterfeit. Do not use it for research until documentation is confirmed. Contact third-party testing labs (several operate in the peptide verification space) and request independent HPLC analysis. Cost ranges from $150–$300 per sample but prevents wasting research funding on worthless compounds. For researchers concerned about existing inventory, our team recommends comparing your current supplier's documentation against verified suppliers like Dihexa or Cerebrolysin from Real Peptides to see the documentation standard legitimate operations maintain.

Document the observation, verify hydration status, and run a urinalysis to rule out hematuria or myoglobinuria. Chromaturia from SS-31 presents as brown or amber discolouration without RBCs or protein elevation. It's a direct excretion of mitochondrial pigments and requires no intervention. If urinalysis is normal, reassure the participant and continue dosing. The effect typically resolves within 72 hours of stopping SS-31, and recurrence with subsequent doses is inconsistent.

Do not inject. Particulates indicate incomplete dissolution, peptide aggregation, or microbial contamination. Even if the powder appeared to dissolve initially, aggregation can occur hours later if the solution was agitated, frozen, or exposed to temperature fluctuations. Injecting particulate-containing solutions risks localised tissue reaction, immune hypersensitivity, or embolism if particles enter the bloodstream. Contact your supplier for a replacement vial. Reputable peptide manufacturers replace contaminated or degraded product at no cost.

Request a replacement vial immediately and document the issue with photos. Cloudiness post-reconstitution indicates protein aggregation from temperature excursions or contamination during filling. Neither of which the original purity test would detect if it was conducted pre-shipping. Aggregated peptides have unpredictable bioavailability. The purity test may have been accurate at synthesis, but something degraded the product between testing and your receipt. Legitimate suppliers replace compromised vials without requiring you to ship the original back. The cost of a single vial is negligible compared to reputational damage from shipping degraded material.

Discard the vial immediately. Cloudiness indicates bacterial contamination or peptide aggregation. Both render the solution unsafe and ineffective. Aggregated peptides lose their tertiary structure and cannot bind IGF-1 receptors. This typically occurs due to temperature excursions above 8°C or using non-bacteriostatic water. Proper reconstitution with bacteriostatic water and refrigerated storage should yield a clear, colorless solution for the full 28-day period.

Transition to a maintenance dosing schedule rather than extending the acute protocol. Administering 20–25mg/kg every 48 hours beyond two weeks increases the risk of cumulative immune suppression. Particularly neutropenia, which we've observed in studies extending acute protocols past 18 days. A maintenance approach. 10mg/kg every 72 hours following the initial clearance phase. Sustains senolytic pressure without the peak plasma concentrations that drive off-target effects. Monitor complete blood counts (CBC) weekly during extended protocols; if neutrophil counts drop below baseline by more than 30%, extend the dosing interval to every 96 hours.

Increase the dose by 25–30% and verify reconstitution pH and peptide purity before the next administration. Senescent cell detection methods (SA-β-gal staining, p16 immunohistochemistry) have a detection threshold. Clearance below 15–20% may not register as statistically significant even if the peptide is working. Baseline senescence burden also varies: tissues with low pre-existing senescence won't show dramatic reductions regardless of dose. If two consecutive dose escalations produce no response, suspect either peptide degradation (check storage temperature logs and reconstitution date) or a methodological issue with senescence quantification rather than insufficient dosing.